Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvedBy |
gptkb:FDA
2016 |
| gptkbp:ATCCode |
gptkb:L04AC13
|
| gptkbp:brand |
gptkb:Taltz
|
| gptkbp:CASNumber |
1143503-51-0
|
| gptkbp:contraindication |
active infections
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:drugClass |
immunosuppressant
|
| gptkbp:form |
solution for injection
|
| https://www.w3.org/2000/01/rdf-schema#label |
ixekizumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:IL-17A
|
| gptkbp:mechanismOfAction |
inhibits IL-17A activity
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
nausea
injection site reactions upper respiratory tract infections |
| gptkbp:target |
gptkb:interleukin-17A
|
| gptkbp:UNII |
8LJ08V8A5V
|
| gptkbp:usedFor |
gptkb:psoriatic_arthritis
ankylosing spondylitis plaque psoriasis |
| gptkbp:bfsParent |
gptkb:interleukin-17A
gptkb:Taltz |
| gptkbp:bfsLayer |
6
|